“Everything should be made as simple as possible, but not simpler” – A. Einstein

The AGGAbody platform was co-developed with researchers at BOKU, Austria and enables the isolation of heterodimeric Fc fusion proteins through a simple purification strategy. The minimal engineering involved has resulted in a heterodimeric Fc fragment with wild-type like properties. Virtually any protein or peptide molecule can be incorporated in a number of combinations and orientations which opens up new targeting and therapeutic possibilities. Recent work with antigen binding scaffolds has shown the dramatic effect that both relative positioning and bi- and tri-specificity can have.


Examples of AGGAbody enabled heterodimeric Fc fusion formats

The AGGAbody platform also enables the generation of mono- and bi-specific antibody like formats. For certain targets a 1:1 interaction is important.

Bispecific scFv-AGGAbody

Bispecific scFv-AGGAbody

mAb1/2

mAb1/2

Common light chain bispecific mAb

Common light chain bispecific mAb